arrow_back Back to App

Multi-Cancer Early Detection: New Tests Covered by Medicare

This act introduces coverage for innovative multi-cancer early detection screening tests under the Medicare program. This means seniors and other Medicare beneficiaries will gain access to advanced screenings that can help diagnose various cancers earlier. These tests will be available once every 11 months, aiming to improve early cancer detection.
Key points
Medicare will cover new multi-cancer early detection screening tests, including genomic sequencing blood tests.
These tests will be available to eligible individuals once every 11 months, increasing the chances of early disease detection.
The act does not affect existing coverage for other cancer screenings like breast, cervical, colorectal, lung, or prostate cancer tests.
A study will be conducted to analyze the utilization of these tests and their impact on health outcomes and access across different demographics.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1873
Sponsor: Sen. Crapo, Mike [R-ID]
Process start date: 2021-05-27
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1873.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-05-27.

What are the main provisions?

Key points include:

  • Medicare will cover new multi-cancer early detection screening tests, including genomic sequencing blood tests.
  • These tests will be available to eligible individuals once every 11 months, increasing the chances of early disease detection.
  • The act does not affect existing coverage for other cancer screenings like breast, cervical, colorectal, lung, or prostate cancer tests.
  • A study will be conducted to analyze the utilization of these tests and their impact on health outcomes and access across different demographics.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Crapo, Mike [R-ID].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health